Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementCommunity Health Plan Washington opioid prior auth…
    Ask Trek AI about this page
    CurrentCommunity Health Plan WashingtonPolicy N/A

    Opioid Agonist Prescribing and Prior Authorization

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs coverage and prior authorization for opioid agonist prescriptions for non-cancer, non-palliative, non-hospice, non-end-of-life pain for Community Health Plan Washington members; affects prescribers and pharmacies dispensing opioids.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyOpioid Agonist Prescribing and Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateNov 1, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization with a signed Opioid Attestation for chronic opioid use (>42 days in 90) and document required assessments and monitoring.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    120max routine daily MME
    200

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    case-by-case threshold
    42adult max dosages (acute)
    18child max dosages (≤20)
    42 dayschronic use definition

    Coverage criteria for opioid prescribing

    Initial and ongoing opioid prescribing criteria

    Covered when ALL of the following are met

    MME limits: Daily MME must not exceed 120 MME for routine coverage; all single or combined opioid claims that cumulatively exceed 120 MME/day but are ≤200 MME/day require consultation with a pain management specialist; claims that cumulatively exceed 200 MME/day will be reviewed case-by-case for medical necessity and require chart notes and a pain specialist consultation.<=120 MME/day; 120–200 MME/day consult; >200 MME/day case-by-case

    Exceptions exist for cancer, hospice, palliative, or end-of-life care and other specified exceptions.

    Acute short-acting opioid limits: Adults (≥21 years): quantity limit of 42 dosages per prescription up to and including 120 MME/day. Children (≤20 years): quantity limit of 18 dosages per prescription up to and including 120 MME/day. Days supply: up to and including 42 calendar days of opioid use within a rolling 90-day period. Use of any opioid(s) for more than 42 days in a 90-day period is considered chronic use and requires prior authorization.42 dosages (adults); 18 dosages (children); <=42 days in 90-day rolling period

    Only short-acting opioids authorized for acute pain; long-acting opioids for acute use require exception criteria.

    Chronic opioid use authorization: Authorization for chronic non-cancer pain requires submission of a signed Opioid Attestation form documenting ongoing clinical need for the prescribed dose (not to exceed 120 MME/day), use or documented trial of appropriate non-opioid medications and/or non-pharmacologic therapies, baseline and ongoing measurable objective pain and function assessments, periodic urine drug screens, PDMP check, discussion of goals and discontinuation options, and a signed pain contract or informed consent. Attestation requests will not be accepted until the patient has been on opioid therapy for at least 25 days in a 90-day period.Attestation after >=25 days on therapy in 90-day period

    Authorization may be granted up to 12 months; attestation must be signed by a prescriber who has written an opioid for the patient within the previous 90 days.

    Exceptions allowing override of quantity/days supply limits include indication of 'CANCER PAIN', 'HOSPICE', 'PALLIATIVE CARE', or 'END OF LIFE CARE' on the prescription (EA code 85000000540) or use of 'EXEMPT' for other medically necessary needs (EA code 85000000541); these exceptions permit overrides of quantity/day limits but do not override the 120 MME/day limit unless other exception criteria are met.EA codes as specified

    Pharmacy must document source and date if criteria are provided telephonically.

    Exceptions to MME limits

    Authorization to exceed 120 MME/day (special circumstances)

    Authorized scenarios: May authorize >120 MME/day up to 200 MME/day when either: (1) patient received an opioid prescription from an emergency department or urgent care associated with a hospital for no more than a 10-day supply (may be authorized up to twice in a 12-month period); OR (2) the prescriber has submitted a signed Opioid Attestation documenting that the patient is on chronic opioid therapy and requires escalation to >120 MME/day but ≤200 MME/day for no more than 42 days, or is following a tapering schedule starting >120 MME/day but ≤200 MME/day, or has a documented medically necessary need to exceed 120 MME/day; AND the prescriber meets required qualifications or obtains consultation with a pain management specialist.<=200 MME/day for specified durations

    Prescriber qualifications include listed WACs, completion of ≥12 continuing education hours on chronic pain (with ≥2 hours on substance use disorders), practice in a multidisciplinary chronic pain center/academic facility, ≥3 years clinical experience, or obtaining consultation with a pain management specialist.

    This policy does not apply to opioid prescriptions written for patients receiving active cancer treatment, hospice care, palliative care, or end-of-life care when the prescriber indicates one of these conditions on the prescription. When the prescriber documents 'CANCER PAIN', 'HOSPICE', 'PALLIATIVE CARE', or 'END OF LIFE CARE' on the prescription, pharmacies may submit the claim with EA code 85000000540 to override the quantity and days-supply limits for short-acting opioids. Note that this exception does not override the 120 MME/day maximum unless other exception criteria are met and documented.

    Opioid prescriptions that exceed the limits specified in this policy will be considered not medically necessary unless an applicable exception, required attestation, specialist consultation, or sufficient clinical documentation is provided. Routine coverage is limited to 120 MME per day; single or combined opioid claims that cumulatively exceed 120 MME/day but are ≤ 200 MME/day require consultation with a pain management specialist, and doses that exceed 200 MME/day will be reviewed on a case-by-case basis with chart notes and a pain specialist consultation required.

    Covered products and definitions used for coding

    Covered opioid ingredients (by product FDA-approved for pain)mixed
    benzhydrocodoneingredient listed
    buprenorphineingredient listed (pain indications only)
    butorphanolingredient listed
    codeineingredient listed
    dihydrocodeineingredient listed
    fentanylingredient listed
    hydrocodoneingredient listed
    hydromorphoneingredient listed
    levorphanolingredient listed
    meperidineingredient listed
    1–10 of 16
    1/2
    inv-06: Chronic use definition
    DefinitionChronic opioid use: Greater than 42 days of opioid use in a 90‑day period.
    ContextUse of any opioid(s) for more than 42 days within a rolling 90‑day period is considered chronic use and requires prior authorization.
    Related limitMaximum daily MME for chronic use limited to 120 MME per day unless an approved exception applies.

    Provider requirements and prior authorization

    Denial Risk

    Dose over MME limits — dosing thresholds and required documentation

    Use of opioids is limited to 120 MME per day. All single or combined opioid claims that cumulatively exceed 120 MME per day but are no more than 200 MME per day require consultation with a pain management specialist and documentation of the exception. Claims that cumulatively exceed 200 MME per day will be reviewed on a case-by-case basis for medical necessity; chart notes including a consultation with a pain specialist for the requested dose are required. Authorization for doses above 120 MME/day may be allowed only under the documented exception criteria (see items).

    • Maximum daily MME limit = 120 MME/day (standard).
    • 120–200 MME/day: requires consultation with a pain management specialist and documented exception.
    • >200 MME/day: case-by-case review; require chart notes and pain specialist consultation.
    • Patients needing >120 MME/day may qualify if: ER/urgent-care opioid prescription ≤10 days (max 2 times/12 months); OR prescriber submits signed Opioid Attestation documenting one of: escalation for chronic therapy ≤200 MME/day for ≤42 days, tapering initiation >120 to ≤200 MME/day, or other medically necessary need; AND prescriber meets specialist or training requirements (see policy).
    • Exceptions may include active cancer treatment, hospice, palliative or end-of-life care (provider must note 'CANCER PAIN', 'HOSPICE', 'PALLIATIVE CARE', or 'END OF LIFE CARE' on the prescription).

    Non-opioid and conservative therapy requirements

    Key definitions used in this policy

    inv-12: Acute opioid use
    DefinitionAcute opioid use: 0 - 42 days of opioid use in a 90‑day period.
    Permitted formulationsOnly short‑acting opioids will be authorized for the treatment of acute pain; long‑acting opioids require exception criteria.
    Quantity and dose limitsAdults: up to 42 dosages per prescription (≤120 MME/day); Children (≤20 years): up to 18 dosages per prescription (≤120 MME/day).
    inv-13: Chronic opioid use
    DefinitionChronic opioid use: Greater than 42 days of opioid use in a 90‑day period.
    Authorization requirementUse beyond 42 days in a 90‑day period is considered chronic and requires prior authorization with a signed Opioid Attestation form.

    Clinical background and rationale

    Opioid agonists are reserved for treatment of severe pain that cannot be managed with non-pharmacologic therapies or non-opioid medications. They exert their effect by acting on central and peripheral opioid receptors and are available in short-acting and long-acting formulations. This policy applies to products FDA-approved for acute or chronic pain that contain listed opioid ingredients and requires that, for chronic use, objective baseline and ongoing assessments (pain and function scores), periodic urine drug screening, PDMP checks, discussion of goals and discontinuation, and a signed pain contract or informed consent be documented in the medical record.

    Exclusions and not-covered indications

    Use of opioids for indications outside FDA-approved pain indications is not covered without a case-by-case review. Requests that fall outside approved pain indications must be supported by clinical justification and will be evaluated for medical necessity on an individual basis.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyOpioid Agonist Prescribing and Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateNov 1, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization with a signed Opioid Attestation for chronic opioid use (>42 days in 90) and document required assessments and monitoring.
    SourceLink
    On This Page
    Coverage criteria for opioid prescribingCovered products and definitions used for codingProvider requirements and prior authorizationNon-opioid and conservative therapy requirementsKey definitions used in this policyClinical background and rationaleExclusions and not-covered indications
    Prior Authorization

    Chronic use prior authorization

    Prior authorization is required for chronic opioid use defined as >42 days of opioid use within a rolling 90-day period. Reauthorization requires an updated, signed Opioid Attestation form; opioid attestation requests for chronic use will not be accepted until the patient has been on opioid therapy for at least 25 days in a 90-day period. Authorization may be granted up to 12 months or the time requested on the attestation, whichever is less.

    • Chronic use = >42 days within a 90-day period.
    • Attestation must be signed by a prescriber who has written an opioid prescription for the patient within the previous 90 days.
    • Reauthorization: updated signed attestation required; may authorize up to 12 months.
    Step Therapy

    Preferred agent trial requirements

    Non-preferred agents require documented inadequate response or intolerance to at least two preferred agents from the Apple Health Preferred Drug List. If only one preferred agent exists in the class, documentation of inadequate response to that one agent is sufficient. New-to-market drugs included in this class per the AHPDL are non-preferred and subject to these PA criteria.

    • Refer to the Apple Health Preferred Drug List: https://www.hca.wa.gov/assets/billers-and-providers/applehealth-preferred-drug-list.xlsx
    • Document trials of TWO preferred agents (or ONE if only one preferred agent exists) showing inadequate response or intolerance.
    Documentation Required

    Required clinical documentation

    Providers must document baseline and ongoing objective pain and function scores, results of periodic urine drug screens, PDMP checks, discussion of goals and discontinuation, and that the patient has signed a pain contract or informed consent. For long-acting opioids, document prior short-acting opioid use for at least 42 days or clinical justification why short-acting opioids are inappropriate or ineffective. Authorization requests must include the required clinical documentation and, when applicable, chart notes supporting exceptions to MME limits.

    • Baseline and ongoing measurable pain and function assessments.
    • Periodic urine drug screening results.
    • Prescription Drug Monitoring Program (PDMP) check documentation and review of concurrent benzodiazepine/sedative use.
    • Discussion with patient of realistic goals and discontinuation options; signed pain contract/informed consent.
    • For long-acting opioids: documentation of ≥42 days short-acting opioid use or clinical justification for starting long-acting therapy.
    Associated MME limitMaximum daily MME for chronic use is limited to 120 MME per day; doses >120 to ≤200 MME/day require pain specialist consultation; >200 MME/day reviewed case‑by‑case.
    inv-14: MME
    DefinitionMME = Morphine milligram equivalent dose as determined using the SUPPORT Act HCA MME Conversion Factors (combines WA AMDG and CDC methodology).
    SynonymAlso called morphine equivalent doses (MED).
    Use in policyMME calculations determine daily dose limits (e.g., 120 MME/day routine limit; 120–200 MME/day requires consultation).